CA2341503C - Probiotic, lactic acid-producing bacteria and uses thereof - Google Patents

Probiotic, lactic acid-producing bacteria and uses thereof Download PDF

Info

Publication number
CA2341503C
CA2341503C CA2341503A CA2341503A CA2341503C CA 2341503 C CA2341503 C CA 2341503C CA 2341503 A CA2341503 A CA 2341503A CA 2341503 A CA2341503 A CA 2341503A CA 2341503 C CA2341503 C CA 2341503C
Authority
CA
Canada
Prior art keywords
bacillus coagulans
administration
antibiotic
per day
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2341503A
Other languages
English (en)
French (fr)
Other versions
CA2341503A1 (en
Inventor
Sean Farmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ganeden Biotech Inc
Original Assignee
Ganeden Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26793455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2341503(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ganeden Biotech Inc filed Critical Ganeden Biotech Inc
Publication of CA2341503A1 publication Critical patent/CA2341503A1/en
Application granted granted Critical
Publication of CA2341503C publication Critical patent/CA2341503C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2341503A 1998-08-24 1999-08-06 Probiotic, lactic acid-producing bacteria and uses thereof Expired - Lifetime CA2341503C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9759498P 1998-08-24 1998-08-24
US60/097,594 1998-08-24
US09/370,793 US6461607B1 (en) 1998-08-24 1999-08-05 Probiotic, lactic acid-producing bacteria and uses thereof
US09/370,793 1999-08-05
PCT/US1999/017862 WO2000010582A2 (en) 1998-08-24 1999-08-06 Probiotic, lactic acid-producing bacteria and uses thereof

Publications (2)

Publication Number Publication Date
CA2341503A1 CA2341503A1 (en) 2000-03-02
CA2341503C true CA2341503C (en) 2011-05-03

Family

ID=26793455

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2341503A Expired - Lifetime CA2341503C (en) 1998-08-24 1999-08-06 Probiotic, lactic acid-producing bacteria and uses thereof

Country Status (8)

Country Link
US (8) US6461607B1 (cg-RX-API-DMAC10.html)
EP (1) EP1107772B1 (cg-RX-API-DMAC10.html)
JP (3) JP5904688B2 (cg-RX-API-DMAC10.html)
AT (1) ATE323503T1 (cg-RX-API-DMAC10.html)
AU (1) AU772332B2 (cg-RX-API-DMAC10.html)
CA (1) CA2341503C (cg-RX-API-DMAC10.html)
DE (1) DE69930944T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000010582A2 (cg-RX-API-DMAC10.html)

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US6716435B1 (en) * 1997-04-18 2004-04-06 Ganeden Biotech, Inc. Absorbent product containing absorbent structure and Bacillus coagulans
AU749001B2 (en) * 1997-04-18 2002-06-13 Ganeden Biotech, Inc. Topical use of probiotic bacillus spores to prevent or control microbial infections
US7507402B1 (en) * 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
US7374753B1 (en) * 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
EP1229923A1 (en) * 1999-11-08 2002-08-14 Ganeden Biotech, Inc. Inhibition of pathogens by bacillus coagulans strains
US6849256B1 (en) * 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
SE515310C2 (sv) * 1999-11-25 2001-07-09 Wasa Medicals Ab Tabletter innehållande mikroorganismer och förfarande för framställning därav
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
ATE320820T1 (de) * 2000-06-28 2006-04-15 B S D Bio Science Dev Snc Di O Pharmazeutische zusammensetzungen von antibiotika und fruktan-gemische
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1322786A4 (en) * 2000-09-11 2005-11-16 Univ Rochester METHOD FOR IDENTIFYING PUTATIVE ANTIBIOTIC RESISTANCE GENES
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
DE10105347A1 (de) * 2001-02-05 2002-08-22 Nutrinova Gmbh Sorbinsäurepräparat enthaltend Probiotika als Futtermittelzusatz in der Nutztieraufzucht
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
US20030124104A1 (en) * 2001-11-05 2003-07-03 Sean Farmer Probiotic compositions
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
AU2002359858A1 (en) * 2001-12-20 2003-07-09 Board Of Trustees Of The University Of Arkansas Defined competitive exclusion cultures for food borne pathogens
GB0212975D0 (en) * 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
ES2329020T3 (es) * 2002-10-18 2009-11-20 Biogaia Ab Procedimiento para potenciar la funcion inmunitaria en mamiferos usando cepas de lactobacillus reuteri.
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
US20040241150A1 (en) * 2002-12-19 2004-12-02 Hargis Billy M. Defined competitive exclusion cultures for food borne pathogens
EP1596872B1 (en) * 2003-01-24 2011-06-22 Flora Technology Inc. Compositions and methods for restoring bacterial flora
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20040175459A1 (en) * 2003-03-06 2004-09-09 Te-Chih Ting Method for producing an aqueous beverage containing sporogenous lactic bacteria
EP1608377B1 (en) * 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
BRPI0408698A (pt) * 2003-03-26 2006-03-28 Cheiron Japan Co alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue
AU2004227998A1 (en) * 2003-04-02 2004-10-21 Pharmachem Laboratories, Inc. Novel probiotic compositions and methods of using the same
US6989370B2 (en) * 2003-05-01 2006-01-24 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
WO2004104175A2 (en) * 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
WO2005000034A2 (en) * 2003-06-23 2005-01-06 Agtech Products, Inc. Lactic bacteria and its use in direct-fed microbials
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
JP4740866B2 (ja) * 2003-10-24 2011-08-03 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
US7632520B2 (en) * 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US20050186188A1 (en) * 2004-02-19 2005-08-25 Peilin Guo Compositions containing probiotics and polysaccharides and methods of use
WO2006113925A2 (en) * 2005-04-20 2006-10-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US7807622B2 (en) * 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US20110117122A1 (en) * 2009-11-16 2011-05-19 Tiffany Thomas COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB
US7374750B2 (en) * 2004-05-14 2008-05-20 Jennifer Albano Probiotic containing anhydrous hair care composition
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
CN1997352B (zh) 2004-06-17 2010-12-01 天野酶制品美国有限公司 含粘膜粘附性聚合物的酶、微生物和抗体的控释制剂
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
CN1997378B (zh) * 2004-07-20 2012-08-08 高台有限公司 天然抗病毒组合物
US7964407B2 (en) * 2004-07-21 2011-06-21 Bates Lynn S Methods of marking products using natural materials having genetically controlled micromorphological structures as markers
US7807468B2 (en) * 2004-07-21 2010-10-05 Bates Lynn S Methods of marking and testing pharmaceutical products
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
WO2006021965A1 (en) * 2004-08-23 2006-03-02 Bharat Biotech International Limited Eukaryotic based synergistic formulation for gastro-intestinal disorders
US20060078546A1 (en) * 2004-10-07 2006-04-13 Anders Zachrisson Use of lactic acid bacteria to reduce sick time
US20060115465A1 (en) * 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US20060093593A1 (en) * 2004-11-04 2006-05-04 Jan Andrejkovic Pro-biotic broad-spectrum nourishment preparation in powder, liquid, paste, or gas form
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
TWI375519B (en) * 2005-02-23 2012-11-01 Otsuka Pharma Co Ltd Tea-based fermentation beverage and tea beverage
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
CA2625818A1 (en) * 2005-04-20 2006-10-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
KR100728585B1 (ko) 2005-05-16 2007-06-15 주식회사 메디오젠 셀레늄을 함유한 유산균 및 이의 제조방법
KR20080015071A (ko) * 2005-06-06 2008-02-18 브리스톨-마이어스스퀴브컴파니 저-피테이트 유아용 조제유
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US20130022577A1 (en) * 2005-09-27 2013-01-24 Cobb & Associates Probiotic compositions useful for treatment of bipolar disorder
WO2007058475A2 (en) 2005-11-15 2007-05-24 Lg Electronics, Inc. Molded articles with antimicrobial property and manufacturing method thereof
US20080057047A1 (en) * 2005-11-29 2008-03-06 Benedikt Sas Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
KR20070067549A (ko) * 2005-12-23 2007-06-28 주식회사 두산 미강 유산균 발효물을 함유하는 피부 보호 및 개선용조성물
AR054730A1 (es) * 2006-02-01 2007-07-11 Allende Miguel Angel Garcia Nuevas bacterias lacticas utiles como probioticos
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
CN101460183A (zh) * 2006-04-10 2009-06-17 亚历山大·弗拉基米罗维奇·迪科夫斯基 肠道吸附剂和益生素组合物、用药形式及消化道紊乱的预防和治疗方法
US20090263416A1 (en) * 2006-06-16 2009-10-22 Dawson Karl A Reduction of antibiotic resistance in bacteria
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008017483A2 (en) * 2006-08-09 2008-02-14 Dsm Ip Assets B.V. Spore surface displays of bioactive molecules
KR20090100357A (ko) * 2006-11-16 2009-09-23 이-테라퓨틱스 리미티드 다중-약물 내성 세균 감염의 치료를 위한 이미다졸
RU2325187C1 (ru) * 2006-11-21 2008-05-27 Александр Владимирович Диковский Фармацевтическая композиция антибиотиков и пребиотиков (варианты) для профилактики и лечения дисбиозов в процессе антибактериальной терапии
ES2328651B1 (es) * 2006-11-29 2010-09-22 Consejo Superior Investigaciones Cientificas Cepa probiotica resistente a antibioticos, producto probiotico que la contiene y sus aplicaciones.
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080175899A1 (en) * 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP3628164A1 (en) * 2007-08-29 2020-04-01 Ganeden Biotech, Inc. Baked goods
EP2638807B1 (en) * 2007-10-16 2021-03-03 Ganeden Biotech, Inc. Beverage compositions
MY161919A (en) * 2008-01-24 2017-05-15 Nestec Sa Capsule with integrated antimicrobial filter
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
US20090305387A1 (en) * 2008-01-30 2009-12-10 Ganeden Biotech, Inc. Compositions and methods for cleaning surfaces
US20110008303A1 (en) * 2008-03-17 2011-01-13 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2009116887A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция антибиотиков и пребиотиков для профилактики и лечения дисбиозов в процессе антибактериальной терапии
HUE025097T2 (en) * 2008-03-18 2016-01-28 Dikovskiy Aleksander Vladimirovich Pharmaceutical preparation for preventing intestinal dysbiosis during antibiotic therapy
US7788209B2 (en) * 2008-05-05 2010-08-31 United Technologies Corporation Hybrid fault reasoning and guided troubleshooting system that uses case-based reasoning and model-based reasoning
US20090280099A1 (en) * 2008-05-07 2009-11-12 Bachman Stephen E Nasopharyngeal inoculate of probiotics and prebiotics for treatment of respiratory infections
JP2011525116A (ja) * 2008-06-24 2011-09-15 マイクロファーマ・リミテッド 一酸化窒素デバイス、ならびに創傷の治癒、皮膚障害および微生物感染症の治療の方法
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
RU2453320C2 (ru) * 2008-08-05 2012-06-20 Виктор Владимирович Чалов Композиция для перорального применения, содержащая непатогенные микроорганизмы, обладающая способностью нормализовать микрофлору кишечника (варианты)
BRPI0918033A8 (pt) * 2008-09-17 2017-10-03 Agraquest Inc Metodo para melhorar a saude de um animal nao inseto e nao humano, e, composicao para melhorar a condicao fisica de um animal nao inseto e nao humano
JP5677304B2 (ja) 2008-10-16 2015-02-25 ガネーデン バイオテック インコーポレイテッド プロバイオティクス穀物組成物
PL213166B1 (pl) * 2008-10-29 2013-01-31 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Sposób otrzymywania farmakologicznej stabilnej formy zliofilizowanych aktywnych preparatów oczyszczonych bakteriofagów
AU2015252095A1 (en) * 2008-12-02 2015-11-19 Dupont Nutrition Biosciences Aps Strains and methods for improving ruminant health and/or performance
ES2590482T3 (es) * 2008-12-02 2016-11-22 Dupont Nutrition Biosciences Aps Cepas y métodos para mejorar la salud y/o el rendimiento de los rumiantes
CA2984935C (en) * 2009-02-24 2021-01-12 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2424550B1 (en) * 2009-04-29 2017-06-07 Ganeden Biotech, Inc. Bacterial cell membrane formulation
US8506952B2 (en) * 2009-07-03 2013-08-13 James Madison Innovations, Inc. Probiotic compositions and process thereof
US8334128B2 (en) 2009-07-17 2012-12-18 Korea Research Institute Of Bioscience And Biotechnology Probiotic spore-forming lactic acid bacteria of Sporolactobacillus vineae strain KCTC 11493BP
US20110027412A1 (en) * 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
BG110506A (bg) 2009-10-27 2011-05-31 "Селур Вк Холдинг" Еоод Нови щамове млечно-кисели бактерии и техни комбинации за получаване на пробиотични препарати
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
KR101695908B1 (ko) 2010-01-28 2017-01-12 시에이치알. 한센 에이/에스 파지 내성에 기초하여 선별된 식품의 텍스처 조절용 유산균
EP4663746A3 (en) 2010-02-01 2026-04-15 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
DE102010009582A1 (de) 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
US20110217275A1 (en) * 2010-03-04 2011-09-08 Joar Opheim Compositions comprising probiotic bacteria of the strain bacillus coagulans and omega-3 polyunsaturated fatty acids or derivatives thereof
WO2011116155A1 (en) 2010-03-17 2011-09-22 Agraquest, Inc. Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
BR112013001107B1 (pt) 2010-07-16 2022-01-25 The Board Of Trustees Of The University Of Arkansas Métodos e composições incluindo bactéria formadora de esporos para aumento da saúde dos animais
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
UA113279C2 (xx) 2010-10-22 2017-01-10 Спосіб забезпечення текстурувального штаму молочнокислих бактерій, його застосування і композиція на його основі
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
MX356959B (es) 2011-05-20 2018-06-21 The Us Secretary Department Of Health & Human Services Cepa paenibacillus alvei ts-15 y su uso en el control de organismos patogenicos.
US9113653B2 (en) 2011-08-19 2015-08-25 Steven J Maranz Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition
DK2748300T3 (en) 2011-08-24 2019-01-14 Dupont Nutrition Biosci Aps ENZYM-PRODUCING BACILLUS STUMS
EA201491932A1 (ru) * 2012-04-23 2015-01-30 Кр. Хансен А/С Устойчивые к ампициллину текстурирующие штаммы молочно-кислых бактерий
KR101390256B1 (ko) 2012-04-26 2014-05-29 울산대학교 산학협력단 ｇｒａＳ 유전자 변이를 이용한 상이 반코마이신 중간내성 황색포도알균 검출용 마커 및 검출방법
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014011564A2 (en) * 2012-07-09 2014-01-16 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
GB2520213A (en) * 2012-08-27 2015-05-13 All Natural Pet Litter Company Pty Ltd Odour controller
US20140112985A1 (en) * 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
WO2014201372A1 (en) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Compounds and methods for affecting cytokines
ITMI20131083A1 (it) * 2013-06-28 2014-12-29 Granarolo S P A Composizione comprendente una specie batterica probiotica
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
DK3060225T3 (da) * 2013-10-25 2024-07-01 Nch Corp Leveringssystem og probiotisk sammensætning til dyr
CA2927360C (en) 2013-10-25 2023-04-18 Nch Corporation Delivery system and probiotic composition for animals and plants
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US9596861B2 (en) 2013-12-24 2017-03-21 Sami Labs Limited Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof
US10716310B2 (en) 2014-03-13 2020-07-21 Phibro Animal Health Corporation Strains of bacillus for inhibiting foodborne pathogens
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
US10766799B2 (en) 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
MX362573B (es) 2014-05-23 2019-01-23 Nch Corp Metodo para mejorar la calidad del agua de un estanque de acuicultura.
CA2955111A1 (en) * 2014-08-29 2016-03-03 Muhammed Majeed Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
WO2016073981A1 (en) * 2014-11-07 2016-05-12 BiOWiSH Technologies, Inc. Antibacterial compositions and methods of use
ES2972377T3 (es) 2015-02-16 2024-06-12 Zivo Bioscience Inc Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CN114366759A (zh) 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PL3307289T3 (pl) 2015-06-09 2022-01-17 Rebiotix, Inc. Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)
KR102713511B1 (ko) * 2015-06-29 2024-10-04 훼링 비.브이. 세균성 질증의 치료를 위한 락토바실러스 람노서스 박테리아
JP2019509263A (ja) 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
AU2017240064B8 (en) 2016-03-31 2021-11-11 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
JP2019510037A (ja) 2016-03-31 2019-04-11 ゴジョ・インダストリーズ・インコーポレイテッド 抗菌ペプチド刺激性洗浄組成物
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
MY190858A (en) 2016-04-05 2022-05-12 Nch Corp Nutrient rich germinant composition and spore incubation method
US12097226B2 (en) 2016-04-05 2024-09-24 Nch Corporation System and method for using a single-serve nutrient spore composition for small scale farm applications
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
IT201600083376A1 (it) * 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
CA2959252C (en) 2016-10-03 2025-06-03 Bio-Cat, Inc. Bacillus compositions and uses thereof
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US20190269740A1 (en) * 2016-10-26 2019-09-05 Nutech Ventures Use of probiotic bacterial strains and cell extracts to inhibit acidosis and liver abscesses in cattle
US20190343761A1 (en) * 2016-11-16 2019-11-14 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
WO2018098152A1 (en) 2016-11-23 2018-05-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
JP7166280B2 (ja) 2016-12-20 2022-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発作を抑制する組成物及び方法
SG11201908472VA (en) 2017-02-15 2019-10-30 Univ California Compositions and methods for activating nk cells
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US12011469B2 (en) * 2017-05-23 2024-06-18 Vireo Systems, Inc. Parenteral delivery device and methods of use
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
AU2018282067B2 (en) * 2017-06-06 2022-01-27 Sami Labs Limited Skin care applications of extracellular metabolites from Bacillus coagulans
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
US10849938B2 (en) * 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
US12194142B2 (en) 2017-09-25 2025-01-14 Deerland Enzymes, Inc. Bacillus subtilis containing composition for treatment of gastrointestinal irregularity
WO2019070983A1 (en) * 2017-10-04 2019-04-11 NCH Life Sciences LLC Nutrient-spore formulations and uses thereof
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
WO2019195592A1 (en) * 2018-04-04 2019-10-10 The University Of Chicago Genetically-engineered microbes and compositions thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11401500B2 (en) 2018-08-29 2022-08-02 Nch Corporation System, method, and composition for incubating spores for use in aquaculture, agriculture, wastewater, and environmental remediation applications
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
US20210378261A1 (en) * 2018-10-02 2021-12-09 Nutech Ventures Novel gras probiotic bacterial strain to inhibit acidosis and liver abscesses in cattle
WO2020076800A1 (en) * 2018-10-09 2020-04-16 Locus Ip Company, Llc Compositions and methods for reducing atmospheric methane and nitrous oxide emissions
JP2019013247A (ja) * 2018-10-19 2019-01-31 株式会社東洋新薬 経口用組成物
IT201800009755A1 (it) 2018-10-24 2020-04-24 Berardino Vaira Nuovi probiotici utili per eradicare l'infezione da helicobacter pylori
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
CN113853198A (zh) 2019-04-09 2021-12-28 德慕拜昂生物科技公司 用于改善皮肤健康和用于治疗和预防与病原微生物相关联的疾病、疾患和病症的组合物和方法
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
MX2022002101A (es) 2019-08-22 2022-03-17 Microbial Discovery Group Llc Metodos de inhibicion con cepas microbianas y antibioticos.
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN110878266B (zh) * 2019-11-21 2021-04-20 中国农业科学院兰州兽医研究所 一株约氏乳杆菌及其用途
KR102116686B1 (ko) * 2020-01-02 2020-05-29 주식회사 쎌바이오텍 성장 인자를 포함하는 유산균 증식 촉진용 조성물
US20230036959A1 (en) * 2020-01-03 2023-02-02 South Dakota Board Of Regents Technology Transfer Office Bile tolerant probiotics to inhibit enteric pathogens
WO2021159068A1 (en) 2020-02-06 2021-08-12 Nch Corportion Composition and method of using germinative compounds in probiotics for inflammation reduction in humans
CN111826314B (zh) * 2020-07-20 2023-04-07 上海交通大学 L-乳酸的生产菌株凝结芽孢杆菌h-2及l-乳酸的生产方法
BR112023002974A2 (pt) 2020-08-21 2023-04-04 Microbial Discovery Group Llc Cepas microbianas e antibióticos
US12514885B2 (en) 2020-08-21 2026-01-06 Microbial Discovery Group, Llc Microbials and antibiotics
JP2023546022A (ja) 2020-10-08 2023-11-01 ジーバイオティクス カンパニー 腸内での繊維合成酵素の発現のための操作されたプロバイオティクス
PL4255203T3 (pl) 2020-12-04 2026-07-20 Compagnie Gervais Danone Acetobacter do zastosowania do wytwarzania fermentowanych produktów
WO2022118076A1 (en) 2020-12-04 2022-06-09 Compagnie Gervais Danone Fermented beverages and processes of preparing the same
WO2022190004A1 (en) * 2021-03-10 2022-09-15 Superbrewed Food, Inc. Antibiotic-resistant probiotics and uses thereof
EP4447984A4 (en) 2021-12-13 2025-12-17 Univ California COMPOSITIONS AND METHOD FOR MODIFYING BILICE ACIDS TO REGULATE LIPIDE AND STERODONTIC METABOLISM
CN114507629B (zh) * 2022-04-19 2022-07-22 中国科学院烟台海岸带研究所 水产养殖益生菌及其菌剂制备与应用
WO2024077194A2 (en) * 2022-10-05 2024-04-11 Microbial Discovery Group, Llc Direct-fed microbials using b. coagulans
KR102623909B1 (ko) * 2022-11-09 2024-01-12 (주)진바이오텍 Escherichia coli 유래 가축 장내 바이오 필름 억제능을 가지는 미생물 균주
CN120897735A (zh) * 2023-03-31 2025-11-04 第一三共健康事业株式会社 含芽孢乳酸菌的口腔用组合物
CN117264806B (zh) * 2023-07-21 2024-05-14 无锡爱科派生物科技有限公司 一株凝结魏茨曼氏菌及其在抑制口腔致病菌中的应用
WO2026096387A1 (en) 2024-10-30 2026-05-07 Bloom Science, Inc. Probiotics and methods to reduce weight

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091572A (en) * 1962-07-16 1963-05-28 Schering Corp Gentamycin and method of production
GB1040278A (en) 1963-10-15 1966-08-24 Analyses Et De Rech S Biolog M Bacterial compositions for the regeneration of the intestinal microflora
US3840684A (en) 1970-03-13 1974-10-08 Gen Foods Corp Decaffeinated coffee
US4323651A (en) 1974-12-04 1982-04-06 R. J. Reynolds Tobacco Company Thermostable lactase derived from bacillus
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4110477A (en) 1977-05-13 1978-08-29 Kabushiki Kaisha Naruse Fermentation Laboratory Method for producing natto containing lactic acid bacteria
US4321258A (en) 1980-08-13 1982-03-23 Dunlap Dorsey S Non-toxic insecticide
CA1206108A (en) 1981-03-06 1986-06-17 Shuichi Aiba Process for transforming microorganism by means of plasmid introduction
FR2569723B1 (fr) 1984-08-31 1986-09-19 Centre Nat Rech Scient Application des antibiotiques de la famille des phleomycines a titre d'agent de selection dans le domaine du genie genetique
US4756913A (en) * 1985-09-30 1988-07-12 Khorkova Evgenia A Sour milk product
US4956177A (en) * 1985-11-04 1990-09-11 Microlife Technics, Inc. Method for inhibiting fungi
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
JPS6483025A (en) 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
DK686187D0 (da) 1987-12-23 1987-12-23 Hansens Chr Bio Syst Veterinaert praeparat
JPH01199575A (ja) 1988-02-04 1989-08-10 Rikagaku Kenkyusho 新規なサイクロマルトデキストリン・グルカノトランスフェラーゼ及びその製造法
IT1227154B (it) 1988-08-05 1991-03-19 A Tosi Farmaceutici S R L Nova Composizioni farmaceutiche per uso ginecologico a base di lattobacilli
AT391323B (de) 1989-03-10 1990-09-25 Jungbunzlauer Ag Mikroorganismus der species bacillus coagulans sowie ein verfahren zur herstellung von optisch reiner l(+)-milchsaeure
FR2656314B1 (fr) 1989-12-22 1992-04-17 Bp Chemicals Snc Catalyseur a base de zirconium supporte sur du chlorure de magnesium, procede de preparation et utilisation du catalyseur dans la polymerisation des olefines.
DE4001611C1 (cg-RX-API-DMAC10.html) 1990-01-20 1991-02-28 Skw Trostberg Ag, 8223 Trostberg, De
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
US5200336A (en) 1990-07-02 1993-04-06 New England Biolabs, Inc. Restriction endonuclease obtainable foam bacillus coagulans and a process for producing the same
JPH0482827A (ja) * 1990-07-23 1992-03-16 Snow Brand Milk Prod Co Ltd 腸溶性カプセル
JPH0667308B2 (ja) 1990-10-24 1994-08-31 田鶴子 藤原 コーヒーによる日本茶及びドクダミの呈味改善方法並びに飲料用組成物
DE4132296C1 (en) * 1991-09-27 1992-12-17 Karl Heinz 8081 Schoengeising De Hoelzel Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut
IT1262927B (it) 1992-01-14 1996-07-22 Consiglio Nazionale Ricerche Batteri sporgenti e loro impiego come probiotici
JP3459837B2 (ja) * 1992-05-12 2003-10-27 太陽化学株式会社 生菌粉末
WO1994011492A1 (en) 1992-11-12 1994-05-26 Chr. Hansen's Laboratory, Inc. Method of favorably modifying poultry intestinal microflora
US5589381A (en) * 1994-06-30 1996-12-31 Rutgers, The State University Of New Jersey Bacillus licheniformis producing antifungal agents and uses thereof for control of phytopathogenic fungi
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5531988A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Bacteria and immunoglobulin-containing composition for human gastrointestinal health
JPH08175921A (ja) 1994-12-22 1996-07-09 Idemitsu Kosan Co Ltd 農園芸用殺菌剤組成物
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
US5785990A (en) 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
AU1758197A (en) * 1996-02-14 1997-09-02 Procter & Gamble Company, The Urogenital and intestinal compositions
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
DE29724815U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
CA2292536A1 (en) 1997-06-03 1998-12-10 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with sids
US7374753B1 (en) * 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
JP3652866B2 (ja) 1997-12-18 2005-05-25 花王株式会社 有胞子乳酸菌を含有する飲料
US5895672A (en) 1998-01-13 1999-04-20 Cooper; Barry Patrick Wesley Product and process for preparing a tea extract
JPH11335285A (ja) 1998-05-25 1999-12-07 Toyotama Koryo Kk 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
JP2002522393A (ja) 1998-08-07 2002-07-23 ガネデン バイオテック， インコーポレイテッド 共生乳酸産生細菌を使用する、栄養材料の溶解度を増大するための方法
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP2000093162A (ja) 1998-09-24 2000-04-04 Kao Corp 有胞子乳酸菌の培養方法
US6080401A (en) 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
EP1020123A1 (en) 1999-01-18 2000-07-19 Sitia-Yomo S.p.A. Beverages containing live lactic bacteria
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6849256B1 (en) * 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
JP2001252012A (ja) 2000-03-15 2001-09-18 Otsuka Shokuhin Kk 長期間チルド保存可能な乳酸菌飲料およびその製造方法
JP3363438B2 (ja) 2000-05-02 2003-01-08 ビオフェルミン製薬株式会社 噴霧乾燥による菌体乾燥物
US9292516B2 (en) 2005-02-16 2016-03-22 Sonic Solutions Llc Generation, organization and/or playing back of content based on incorporated parameter identifiers
US7024497B1 (en) 2000-09-07 2006-04-04 Adaptec, Inc. Methods for accessing remotely located devices
JP2002085009A (ja) 2000-09-14 2002-03-26 Unicafe Inc 納豆末を用いた腸内活性化食品
US20030185811A1 (en) 2001-02-06 2003-10-02 Steve Teasdale Herbal extract and preparation thereof
US6599555B2 (en) 2001-03-08 2003-07-29 Bocabear Foods, Inc. Process for making a reduced-calorie fruit and/or vegetable spread
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
WO2004004747A1 (ja) 2002-07-09 2004-01-15 Decentwork Inc. 整腸性組成物及び整腸健康飲料並びに大腸内洗浄液
US20040010510A1 (en) 2002-07-10 2004-01-15 Timo Hotti Method and system for database synchronization
ATE412339T1 (de) 2002-07-19 2008-11-15 Suedzucker Ag Isomaltulose-haltige instant-getränkepulver enthaltend harnstoff
TWI228974B (en) 2002-09-04 2005-03-11 Genmont Biotech Inc Beverage containing lactobacillus and the manufacturing method thereof
US20040071685A1 (en) 2002-10-09 2004-04-15 Devin Houston Compositions and methods for increasing the bioavailability of plant polyphenols
CN1221187C (zh) 2002-12-13 2005-10-05 景岳生物科技股份有限公司 含乳酸菌的饮用品及其制造方法
US20040175459A1 (en) 2003-03-06 2004-09-09 Te-Chih Ting Method for producing an aqueous beverage containing sporogenous lactic bacteria
AU2004233658B2 (en) 2003-03-13 2009-10-29 Kirin Holdings Kabushiki Kaisha Antiallergic composition
JP2004337125A (ja) 2003-05-19 2004-12-02 Ajinomoto Co Inc 有胞子乳酸菌胞子を含有するインスタントスープ
US20070059400A1 (en) 2003-07-18 2007-03-15 Toyo R & D Inc Composition containing ground lotus and/or lotus extract and lactic acid bacterium
AU2004267383A1 (en) 2003-08-14 2005-03-03 The Bio Balance Corporation Bacterial strains, compositions including same and probiotic use thereof
CA2544605C (en) 2003-11-14 2013-07-02 Sonic Solutions Secure transfer of content to writable media
JP2007082403A (ja) 2004-03-26 2007-04-05 Nippon Medicine:Kk ユッカ抽出物、キラヤ抽出物及び乳酸菌の複合組成物を含有する飲食品及びその製造法
JP2007308373A (ja) 2004-06-03 2007-11-29 Toyo Shinyaku:Kk 腸内菌叢改善剤
JP4296133B2 (ja) 2004-07-12 2009-07-15 カゴメ株式会社 チルド飲料およびその製造方法
MX2007006324A (es) 2004-11-29 2007-10-17 Aloecorp Inc Deshidratacion de combinaciones de alimentos.
TWI375519B (en) 2005-02-23 2012-11-01 Otsuka Pharma Co Ltd Tea-based fermentation beverage and tea beverage
JP2006254837A (ja) 2005-03-18 2006-09-28 Kyoto Institute Of Technology 乳酸菌機能茶、乳酸菌機能茶抽出物、乳酸菌機能茶葉乾燥物
JP2007000140A (ja) 2005-05-25 2007-01-11 Suntory Ltd 乳酸菌を用いたコーヒー生豆の処理方法
JP4332743B2 (ja) 2005-08-12 2009-09-16 天野実業株式会社 発酵食品由来の有胞子性乳酸菌を含有する乾燥食品
US7555715B2 (en) 2005-10-25 2009-06-30 Sonic Solutions Methods and systems for use in maintaining media data quality upon conversion to a different data format
US20090257995A1 (en) 2005-11-18 2009-10-15 Idemitsu Kosan Co., Ltd. Harmful bacterium control agent containing bacillus thuringiensis
US7758906B2 (en) 2006-01-20 2010-07-20 Kraft Foods Global Brands Llc Thickening system for products prepared with milk
US20100098806A1 (en) 2007-03-13 2010-04-22 Vdf Futureceuticals, Inc. Compositions and Methods of Dehydrated Food Fortification
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
EP2638807B1 (en) 2007-10-16 2021-03-03 Ganeden Biotech, Inc. Beverage compositions

Also Published As

Publication number Publication date
US8187590B2 (en) 2012-05-29
US20030031659A1 (en) 2003-02-13
DE69930944T2 (de) 2007-01-04
US20140242051A1 (en) 2014-08-28
US7807151B2 (en) 2010-10-05
CA2341503A1 (en) 2000-03-02
WO2000010582A2 (en) 2000-03-02
DE69930944D1 (de) 2006-05-24
JP5904688B2 (ja) 2016-05-18
US20080233104A1 (en) 2008-09-25
AU5341599A (en) 2000-03-14
US20120177620A1 (en) 2012-07-12
EP1107772A2 (en) 2001-06-20
US20110020305A1 (en) 2011-01-27
WO2000010582A3 (en) 2000-07-13
US8697055B2 (en) 2014-04-15
JP2010215665A (ja) 2010-09-30
WO2000010582A8 (en) 2001-05-25
US6461607B1 (en) 2002-10-08
JP2002523372A (ja) 2002-07-30
EP1107772B1 (en) 2006-04-19
JP2015061882A (ja) 2015-04-02
US8097247B2 (en) 2012-01-17
US7708988B2 (en) 2010-05-04
US20110020306A1 (en) 2011-01-27
AU772332B2 (en) 2004-04-22
US20060099197A1 (en) 2006-05-11
ATE323503T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
US8697055B2 (en) Probiotic, lactic acid-producing bacteria
US6849256B1 (en) Inhibition of pathogens by probiotic bacteria
AU750136B2 (en) Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US7374753B1 (en) Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
AU785159B2 (en) Inhibition of pathogens by bacillus coagulans strains
WO2000007606A2 (en) Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
EP1719518A1 (en) Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190806